How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

Figures & data

Figure 1. Epidemiological inputs.

Abbreviations: HZ, herpes zoster; OWSA, one-way sensitivity analysis; PHN, post-herpetic neuralgia.

*Base case values ±20%.

^†The first-dose values were approved by an advisory board, based on data from the ZOE-50, ZOE-70, and ZOE-LTFE studies.

^‡The age-specific values for HZ and PHN incidence and recurrence rates and vaccine efficacy were each varied concurrently in the OWSAs, while the age-specific values for waning were varied separately.

^¶For neurological complications, the percentages for meningoencephalitis and Ramsay-Hunt syndrome from Antoniolli et al.⁴³ were added together, as the value for meningoencephalitis was much lower than in other sources.^45,46

^#For other complications, the percentage with Ramsay-Hunt syndrome from Antoniolli et al.⁴³ was used.

Figure 2. Numbers of cases of HZ, PHN, and non-PHN complications without RZV and avoided with RZV, by country, overall, and by age group.

The sum of the country results may not equal the total due to rounding.

Abbreviations: HZ, herpes zoster; PHN, post-herpetic neuralgia; RZV, recombinant zoster vaccine.

Figure 3. Numbers of cases of ocular, neurological, cutaneous, and other complications without RZV and avoided with RZV by country, overall.

The sum of the country results may not equal the total due to rounding.

Abbreviation: RZV, recombinant zoster vaccine.

Figure 4. Numbers of doctor’s visits and hospitalization days without RZV and saved with RZV.

The sum of the country results may not equal the total due to rounding.

Abbreviation: RZV, recombinant zoster vaccine.

Figure 5. Numbers needed to vaccinate to avoid one case.

Abbreviations: HZ, herpes zoster; PHN, post-herpetic neuralgia.

Figure 6. Deterministic OWSA results (top five inputs per country) for HZ cases avoided for Argentina, Brazil, Mexico, Chile, and Colombia. Light color indicates low values; dark color indicates high values. For input values used, please see Figure 1.

Abbreviations: HZ, herpes zoster; OWSA, one-way sensitivity analysis.

Figure 7. Scenario results of the numbers of cases of HZ avoided using alternative second dose compliance rates.

Abbreviation: HZ, herpes zoster.

Antoniolli L, Rodrigues C, Borges R, Goldani LZ. Epidemiology and clinical characteristics of herpes zoster in a tertiary care hospital in Brazil. Braz J Infect Dis. 2019;23:143–45. doi:10.1016/j.bjid.2019.03.001.

 PubMed Web of Science ®Google Scholar

Abreu AJL, Venys A, Jacob W, Silva T, Henrique A, Gopala K, Barros ENC. Burden of herpes zoster among Brazilian adults – a hospital-based study. Geriatr Gerontol Aging. 2021;15:e0210035. doi:10.53886/gga.e0210035.

 Google Scholar

Bollea-Garlatti ML, Bollea-Garlatti LA, Vacas AS, Torre AC, Kowalczuk AM, Galimberti RL, Ferreyro BL. Clinical characteristics and outcomes in a population with disseminated herpes zoster: a retrospective cohort study. Actas Dermosifiliogr. 2017;108:145–52. doi:10.1016/j.ad.2016.10.009.

 PubMedGoogle Scholar